COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

CRRT for Glutamate Elimination After Cardiac Arrest (GCRRT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02963298
Recruitment Status : Completed
First Posted : November 15, 2016
Last Update Posted : June 21, 2019
Information provided by (Responsible Party):
C. Storm, Charite University, Berlin, Germany

Brief Summary:
Glutamate is known to be a mediator for apoptosis after brain hypoxia e.g. due to cardiac arrest. This pilot trial evaluates the possibility of elimination of Glutamate by CRRT after cardiac arrest.

Condition or disease Intervention/treatment Phase
Reperfusion Syndrome Procedure: Continuous renal replacement therapy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Trial Concerning Glutamate Elimination With CRRT for Neurological Outcome After Cardiac Arrest
Study Start Date : October 2016
Actual Primary Completion Date : September 6, 2017
Actual Study Completion Date : September 6, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cardiac Arrest

Arm Intervention/treatment
Active Comparator: CRRT after cardiac arrest
Continuous renal replacement therapy (CRRT) after cardiac arrest for 72 hours for elimination of Glutamate. Repetitive testing of blood Glutamate levels.
Procedure: Continuous renal replacement therapy
No Intervention: control
Repetitive testing of blood Glutamate levels without CRRT

Primary Outcome Measures :
  1. Glutamate blood concentration in intervention arm over the time [ Time Frame: 72 hours ]
    Reduction of blood Glutamate concentration by renal replacement therapy

Secondary Outcome Measures :
  1. number of participants with abnormal outcome parameters [ Time Frame: up to 14 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • post cardiac arrest

Exclusion Criteria:

  • hemodynamic instable
  • in-hospital cardiac arrest

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02963298

Layout table for location information
Charité-Universitätsmedizin Berlin
Berlin, Germany, 13353
Sponsors and Collaborators
C. Storm
Layout table for investigator information
Principal Investigator: Christian Storm, MD Charite University, Berlin, Germany
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: C. Storm, PD Dr. med., Charite University, Berlin, Germany Identifier: NCT02963298    
Other Study ID Numbers: Glu2016
First Posted: November 15, 2016    Key Record Dates
Last Update Posted: June 21, 2019
Last Verified: June 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Arrest
Heart Diseases
Cardiovascular Diseases